NantKwest and ImmunityBio to Present at the Jefferies Virtual Healthcare Conference

On May 26, 2020 NantKwest, Inc. (NASDAQ: NK) and ImmunityBio, Inc., reported that Patrick Soon-Shiong, M.D., Chairman and CEO of both companies, will present at the Jefferies Virtual Healthcare Conference on June 3, 2020 at 4:30 pm ET (Press release, Altor BioScience, MAY 26, 2020, View Source [SID1234558460]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and can be accessed through the NantKwest and ImmunityBio websites, NantKwest.com and ImmunityBio.com. An archived replay will be available on the websites for approximately 30 days.

Blueprint Medicines to Host Conference Call to Review Updated Clinical Data for Pralsetinib in RET-Altered Cancers on Friday, May 29, 2020

On May 26, 2020 Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, reported that it will host a live conference call and webcast at 8:30 a.m. ET on Friday, May 29, 2020 to review updated clinical data for pralsetinib in RET-altered cancers (Press release, Blueprint Medicines, MAY 26, 2020, http://ir.blueprintmedicines.com/news-releases/news-release-details/blueprint-medicines-host-conference-call-review-updated-clinical [SID1234558476]). The data will also be presented in the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) 2020 (ASCO20) Virtual Scientific Program, May 29-31, 2020.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call Information

To access the live call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international) and refer to conference ID 8585078. A webcast of the conference call will be available in the Investors & Media section of Blueprint Medicines’ website at View Source The archived webcast will be available on Blueprint Medicines’ website approximately two hours after the conference call and will be available for 30 days following the call.

Xencor to Present at Upcoming Investor Conferences

On May 26, 2020 Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, reported that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences (Press release, Xencor, MAY 26, 2020, View Source [SID1234558494]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Virtual Healthcare Conference
Date: Tuesday, June 2, 2020
Presentation Time: 2:30 p.m. ET / 11:30 a.m. PT
Raymond James Human Health Innovation Conference
Date: Monday, June 15, 2020
Immuno-Oncology Panel Time: 11:00 a.m. ET / 8:00 a.m. PT
A live webcast of the presentation at the Jefferies conference will be available under "Events & Presentations" in the Investors section of the Company’s website located at www.xencor.com. A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

Medivir Appoints Yilmaz Mahshid as New CEO

On May 26, 2020 Medivir AB (Nasdaq Stockholm: MVIR) reported that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company (Press release, Medivir, MAY 26, 2020, View Source [SID1234558511]). Yilmaz Mahshid has long and broad experience from qualified roles in the life science sector. He succeeds Uli Hacksell, who has been CEO since October 2018. Yilmaz Mahshid will assume his position in the fall. Uli Hacksell remains as a board member of Medivir.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Yilmaz Mahshid joins Medivir from his recent position as CFO at PledPharma. He was prior to that Investment Manager at Industrifonden. He has also worked as a health care analyst at Pareto Securities and at Öhman Fondkommission. Yilmaz holds a doctorate from the Department of Medical Biochemistry and Biophysics at Karolinska Institute. He began his career as a researcher at the Karolinska Institute followed by the pharmaceutical companies Biolipox and Orexo.

– Uli Hacksell assumed leadership responsibility for Medivir as acting CEO in the fall of 2018 in conjunction with the strengthened focus on clinical cancer projects and a comprehensive restructuring of the company. Uli has invested enormous energy in shaping and developing Medivir into the company it is today. When we looked for Uli’s successor, important parameters were experience, a strong scientific foundation, knowledge and insight about the industry as well as the investor perspective. In Yilmaz Mahshid we have found what we were looking for and it is my great pleasure to welcome him to Medivir", says Helena Levander, Chairman of Medivir’s Board of Directors.

– Going forward, Uli will still be strongly involved in the company’s development in his role as board member. We are extremely grateful that he led the strategically important transformation of Medivir", continues Helena Levander.

– I believe that Yilmaz will be perfect as new CEO of Medivir. He is extremely qualified and has the background, drive and strategic thinking that our exciting company needs. I will stay on as CEO until Yilmaz takes over. Shortly after the handover I will return to function solely as a board member, but I will of course be available as a sparring partner whenever Yilmaz so wishes.", says Uli Hacksell, CEO at Medivir.

Medivir AB is obliged to make this information public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on May 26, 2020.

Interim Report Q1 2020

On May 26, 2020 Oncopeptides reported that Interim Report Q1 2020 (Press release, Oncopeptides, MAY 26, 2020, View Source [SID1234558444])

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Financial overview January 1 – March 31, 2020
Net sales amounted to SEK 0.0 M (0.0)
Loss for the period was SEK 297.3 M (loss: 134.1)
Loss per share, before and after dilution, was SEK 5.37 (loss: 2.82)
On March 31 cash and cash equivalents amounted to SEK 617.8 M (747.5)
Significant events during the period January 1 – March 31, 2020
Top line results from the company’s pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients
The Lancet Haematology published detailed results from Oncopeptides international multi¬center study, O-12-M1
Oncopeptides announced that COVID-19 will not affect the company’s pivotal studies sig¬nificantly while recruitment to explorative studies and initiating new studies will temporar¬ily be paused
The company strengthened its management team with several new senior executives
Significant events after the reporting period
In May, Oncopeptides completed a directed share issue of SEK 1,414 million (144 MUSD) before issue costs
The enrollment in the pivotal phase 3 study OCEAN was successfully completed in May including 450 patients from more than 100 hospitals around the world
Financial overview of the group
2020
Jan – Mar 20191)
Jan – Mar 2019
Jan – Dec
Net sales – – –
Operating loss -296,876 -133,812 -739,392
Loss before tax -297,327 -133,946 -739,920
Loss for the period -297,329 -134,077 -740,705
Earnings per share before and after
dilution (SEK) -5.37 -2.82 -14.33
Cash flow from operating activities -312,841 -142,821 -690,566
Cash and cash equivalents at the end of the period 617,786 747,471 926,186
Research & development costs/operating expenses % 72% 80% 74%
1) Earlier periods have been adjusted to reflect correction of errors, see note 6.

Conference call for investors, analysts and the media
The Interim Report Q1 2020 and an operational update will be presented by CEO Jakob Lindberg and members of Oncopeptides management team, Tuesday May 26, 2020 at 10:00 (CET). The conference call will also be streamed via a link on the website: www.oncopeptides.com.